Eltrombopag is a novel thrombopoietin receptor agonist that has changed the face of treatment of thrombocytopenia, especially in patients with chronic immune thrombocytopenia. The cost of eltrombopag is essentially required to be known by both health care providers and patients, as well as its cost-effectiveness compared to conventional treatments.
Overview of Eltrombopag
Eltrombopag is sold under the brand name Promacta, among others. Eltrombopag is an orally bioavailable thrombopoietin receptor agonist that acts by promoting the generation of platelets by the bone marrow. Therefore, it is a very helpful medication in case of treatment failure with every other type of therapy. It is given orally, and the dosages vary commonly from 12.5 mg to 75 mg.
Cost of Eltrombopag
The cost also varies greatly depending on region and healthcare system. Costs range from $1.87 to $7.03 per milligram in Canada, leading to substantial variation in overall treatment costs. For example, one study using the lowest published cost for eltrombopag demonstrated it was approximately $1,638 cheaper per patient when compared to intravenous immunoglobulin, one of the most common alternative treatments for ITP.
In the United States, the wholesale average Eltrombopag price is about USD 1,200 for a month's supply, depending on the dosage. Of course, many patients are covered and would have a much more modest copay, while others would have to pay the full retail cost of the medication, which is unaffordable to most patients. Some have questioned the cost-effectiveness of eltrombopag, given that treatment may be required for a patient's lifetime.
Cost-Effectiveness Analysis
Recent studies have proved eltrombopag to be cost-effective as compared to IVIg in the perioperative management of ITP. A pivotal study showed that eltrombopag was less costly as compared to IVIg, with a direct cost of around CAD 166,199 for eltrombopag versus CAD 188,660 for IVIg.
Key Findings from the Analysis
1. Direct Costs: The direct costs of eltrombopag were lower compared to those of IVIg, even considering natural variability in treatment protocols and the responses of patients.
2. Success Rates of Treatments: Eltrombopag presented a treatment success rate of 78.9%, while that of IVIg was 61.1%; hence, it is cost-effective for desired clinical results.
3. Sensitivity Analysis: It was noted that as the cost of IVIg increased, the cost saving on behalf of eltrombopag further increased accordingly. For instance, if the highest cost reported for eltrombopag was used, it became more costly than IVIg and, therefore the importance of pricing in treatment decisions was realised .
Implications for Healthcare Providers
The implications of these cost-effectiveness analyses are very significant for healthcare providers and policy makers in general. With the continuous spiral of healthcare costs, the search for effective and affordable treatments is now more urgent than ever. The relatively good cost profile will likely favour the adoption of eltrombopag over more expensive treatments, such as IVIg, at least in resource-poor settings.
Clinical Implications
Clinicians should consider a holistic approach to treating such diseases like ITP by looking into the overall cost of care for various treatment options, which would likely ensure improvement in resource allocation and improved clinical outcome for the patient. The health professional in this regard would also have to be informed about the cost of eltrombopag at any instance so that they can always give the best options for treatment to their patients.
Patient Considerations
For many patients, the cost of medication is one of the leading determinants in treatment adherence. Eltrombopag can be quite challenging, with its variably priced tags, especially to those who do not have good insurance coverage for the drug. Patients are encouraged to discuss potential costs with healthcare providers and explore options, such as patient assistance programs, offered by pharmaceutical companies.
Conclusion
Eltrombopag has become a major development in the treatment of thrombocytopenia, offering economies of scale while sustaining response rates to therapies. In these days of escalating healthcare costs, its use can thus result in significant economic gains for healthcare systems without compromising the delivery of optimal care to patients. The cost of eltrombopag and cost-effectiveness are important considerations that may guide appropriate decision-making in the clinical setting.
More Info: Sofosbuvir price